Bio­phar­ma's deals land­scape could hard­ly be bet­ter, as large com­pa­nies take a mul­ti-pronged ap­proach to with­stand an avalanche of ma­jor patent ex­piries.

But there’s one...

Can­del Ther­a­peu­tics pro­duced long-term fol­low-up da­ta that may bol­ster the case for its prostate can­cer drug that's head­ing to the FDA for mar­ket­ing ap­proval lat­er...

Am­gen is ex­pand­ing its claims da­ta re­quire­ments for phar­ma­cies dis­pens­ing its drugs un­der the 340B fed­er­al drug dis­count pro­gram.

The com­pa­ny said the new pol­i­cy...

The Supreme Court will con­tin­ue to al­low the abor­tion pill mifepri­s­tone to be dis­trib­uted by mail, at least for now.

The Thurs­day rul­ingmain­tains mifepri­s­tone's...

Mar­ty Makary re­signed as FDA com­mis­sion­er on Tues­dayaf­ter a tur­bu­lent tenure at the head of the agency. Makary was sched­uled to sit down with...